HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: ard.2006.059428v1 66/3/325    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Martínez, A. Articles by Urcelay, E. Search for Related Content PubMed PubMed Citation Articles by Martínez, A. Articles by Urcelay, E.

Role of the MHC2TA gene in autoimmune diseases

¹ Immunology Department, Hospital Universitario San Carlos, Madrid, Spain
² Rheumatology Department, Hospital Universitario San Carlos, Madrid, Spain
³ Neurology Department, Hospital Universitario San Carlos, Madrid, Spain
⁴ Gastroenterology Department, Hospital Universitario San Carlos, Madrid, Spain

Correspondence to:
Correspondence to:
Dr E Urcelay
Immunology Department, Hospital Universitario San Carlos, Martin Lagos s/n, 28040 Madrid, Spain; eurcelay.hcsc{at}salud.madrid.org

Objectives: Expression of major histocompatibility complex (MHC) class II genes is almost exclusively regulated by the class II transactivator. A promoter polymorphism (–168A/G, rs3087456) in the MHC2TA gene was associated with increased susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction in a northern European population. However, no evidence of association of this MHC2TA variant with the two autoimmune diseases could be subsequently detected in independent cohorts.

Aim: To test the aforementioned single nucleotide polymorphism and another GC change (nt1614 from coding sequence, rs4774) to analyse the haplotype pattern in this MHC2TA gene.

Methods: A case–control study was performed with 350 patients with rheumatoid arthritis, 396 patients with multiple sclerosis, 663 patients with inflammatory bowel disease (IBD) and 519 healthy controls from Madrid. Genotyping was ascertained by using TaqMan assays-on-demand on a 7900HT analyser, following the manufacturer’s suggestions (Applied Biosystems, Foster City, California, USA). Haplotypes were inferred with the expectation–maximisation algorithm implemented by the Arlequin software.

Results: No independent association with these autoimmune diseases was found for either polymorphism in the Spanish cohorts tested. However, when haplotypes were compared between patients with rheumatoid arthritis and controls, a significant difference in their overall frequency distribution was observed, evidencing a protective haplotype (–168A/1614C, p = 0.006; odds ratio (OR) 0.7) and a risk haplotype (–168G/1614C, p = 0.019; OR 1.6). Patients with multiple sclerosis mirrored these results, but no effect on IBD was identified.

Conclusions: The MHC2TA gene influences predisposition to rheumatoid arthritis and multiple sclerosis, but not to IBD. The –168G allele is not an aetiological variant in itself, but a genetic marker of susceptibility/protection haplotypes.

Abbreviations: CIITA, class II transactivator; HLA, human leucocyte antigen; IBD, inflammatory bowel disease; MHC, major histocompatibility complex